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Abstract 
Background: High-risk human papillomaviruses (HR-HPVs) types 16 and 18 are the main etiological agents of cervi-
cal cancer, with more than 550,000 new cases each year worldwide. HPVs are also associated with other ano-genital 
and head-and-neck tumors. The HR-HPV E6 and E7 oncoproteins are responsible for onset and maintenance of the 
cell transformation state, and they represent appropriate targets for development of diagnostic and therapeutic tools.
Methods: The unmutated E6 gene from HPV16 and HPV18 and from low-risk HPV11 was cloned in a prokaryotic 
expression vector for expression of the Histidine-tagged E6 protein (His6-E6), according to a novel procedure. The 
structural properties were determined using circular dichroism and fluorescence spectroscopy. His6-E6 oncoprotein 
immunogenicity was assessed in a mouse model, and its functionality was determined using in vitro GST pull-down 
and protein degradation assays.
Results: The His6-tagged E6 proteins from HPV16, HPV18, and HPV11 E6 genes, without any further modification in 
the amino-acid sequence, were produced in bacteria as soluble and stable molecules. Structural analyses of HPV16 
His6-E6 suggests that it maintains correct folding and conformational properties. C57BL/6 mice immunized with 
HPV16 His6-E6 developed significant humoral immune responses. The E6 proteins from HPV16, HPV18, and HPV11 
were purified according to a new procedure, and investigated for protein–protein interactions. HR-HPV His6-E6 bound 
p53, the PDZ1 motif from MAGI-1 proteins, the human discs large tumor suppressor, and the human ubiquitin ligase 
E6-associated protein, thus suggesting that it is biologically active. The purified HR-HPV E6 proteins also targeted the 
MAGI-3 and p53 proteins for degradation.
Conclusions: This new procedure generates a stable, unmutated HPV16 E6 protein, which maintains the E6 proper-
ties in in vitro binding assays. This will be useful for basic studies, and for development of diagnostic kits and immuno-
therapies in preclinical mouse models of HPV-related tumorigenesis.
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Background
New human papillomavirus (HPV) types are continu-
ously being described, and 174 have been completely 
characterized. Among these, 47 can infect the ano-genital 
area [1]. While high-risk (HR)-HPVs are commonly asso-
ciated with cancer, low-risk (LR)-HPVs have mostly been 
identified in condyloma acuminatum [2], with HPV6 and 
HPV11 responsible for 90 % of all genital warts.
It is believed that all cervical cancers are caused by 
HPV infections, and that HPV16 and HPV18 are respon-
sible for about 70 % of all cases [3]. HPV16 and HPV18 
have also been shown to cause almost half the vaginal, 
vulvar, and penile cancers, while about 85 % of anal can-
cers are also caused by HPV16 [4]. HPVs, and HPV16 in 
particular, are associated with some head and neck squa-
mous-cell carcinomas, and they are an independent risk 
factor for oropharyngeal cancers [5].
The incidence of HPV-associated oropharyngeal cancer 
has increased over the past 20  years, especially among 
men, and it has been estimated that HPVs will cause 
more oropharyngeal than cervical cancer in the United 
States by 2020 [6].
Currently, routine screening is foreseen only for cervi-
cal cancer, where viral DNA detection (usually by PCR-
based tests) has been used by different countries for 
cervical tumor prevention programs. However, although 
these tests are highly sensitive for the detection of HPVs 
[7, 8], they are not indicative of possible evolution of pre-
cancerous lesions to tumors. The current challenge is 
therefore to develop tests that can better distinguish self-
resolving HPV infections from those that might progress 
to pre-cancer and to cancer.
Recently, HPV16 E6 serology was identified as a prom-
ising pre-diagnostic marker for HPV-driven cancers [9], 
as HPV16 E6 seropositivity has been found more than 
10 years before diagnosis of oropharyngeal cancers [10]. 
It is also important to note that seropositivity is relatively 
common before diagnosis of anal cancer, although it is 
rare for other HPV-related ano-genital tumors [11].
E6 is a potent oncogene of HR-HPVs, and its role in 
progression to malignancy has been, and continues to 
be, explored [12]. The E6 oncoprotein of HPVs targets 
numerous cell pathways to promote viral DNA repli-
cation. It forms a complex with human E3-ubiquitin 
ligase E6-associated protein (E6AP), which can in turn 
target the p53 tumor-suppressor protein, leading to its 
ubiquitin-mediated degradation. In particular, E6 from 
HR-HPVs can block apoptosis, activate telomerase, dis-
rupt cell adhesion, polarity and epithelial differentiation, 
alter transcription and G-protein signaling, and reduce 
immune recognition of HPV-infected cells [13, 14].
The HR-HPV E6 proteins are characterized by a PDZ 
binding motif (PSD95/DLG/ZO-1; a structural domain 
of 80–90 amino-acids) at the carboxy (C)-terminus (e.g., 
RTRRETQL for HPV16 E6). Proteins that contain mul-
tiple PDZ domains are frequently expressed in regions 
of cell-to-cell contact and alterations to these intercel-
lular junctions can destroy tissue organization and favor 
dysplastic events. Through degradation of human discs 
large tumor suppressor (hDLG), the HR-HPV E6 pro-
teins can also alter cell growth and polarity in response 
to cell contact [15]. Other E6 PDZ-domain-containing 
targets include the MAGI proteins, which are members 
of the membrane-associated guanylate kinase homolog 
(MAGUK) family of scaffold molecules that are involved 
in regulation of tight-junction assembly [16]. This func-
tion is significant for E6 oncogenic activity, as deficiency 
in cell polarization is a marker of tumor progression [17].
The E6 protein has about 150 amino-acids, and it is 
characterized by two conserved zinc-finger-like internal 
sequences (i.e., Cx2C-x29-Cx2C). These are joined by an 
inter-domain linker of 36 amino-acids, and are flanked 
by short N-terminal and C-terminal domains of variable 
lengths [18]. Endogenous E6 is expressed at very low lev-
els in HPV-containing cells, and it is subject to nuclear 
import and export processes, which is consistent with its 
targeting of proteins located in either the nucleus [19] or 
the cytoplasm [20].
Due to difficulties in the production of recombinant 
full-length E6 protein in its native and soluble forms, 
there is a lack of clear information about its structure. 
One problem is associated with its high cysteine con-
tent (e.g., 14 cysteines in HPV16 E6). Substitutions of the 
nonconserved cysteines in E6 with serines did not affect 
its activity towards in vitro and in vivo p53 degradation, 
and only marginally helped to make it more soluble [12]. 
E6 fused to the C-terminus of carrier proteins, such as 
maltose-binding protein (MBP-E6) or glutathione-S-
transferase (GST-E6), were overexpressed in Escherichia 
coli in a soluble form, thus allowing these fusion proteins 
to be purified by single-step affinity procedures [21, 22]. 
However, proteolytic removal of the carrier proteins (i.e., 
MBP, GST) led to rapid precipitation of the E6 protein 
[23].
The E6 protein, as either unfused or His-tagged, is 
mainly produced as inclusion bodies [24], but when it is 
fused to the C-terminus of MBP, it appears in the form 
of soluble, high-molecular-weight aggregates [25] that 
can spontaneously assemble into large organized ribbon 
structures [26]. To date, the preparation of the concen-
trated and soluble HPV16 E6 protein has required addi-
tion of a peptide corresponding to the cellular acidic 
leucine (L)-rich (LxxLL) motif of E6AP, substitution of 
nonconserved cysteines, and mutation of the dimeriza-
tion surface in its N-terminal domain [27]. These con-
ditions resulted in the crystallization of HPV16 E6 with 
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the LxxLL peptides of E6AP [28]. Also, the structure of 
the E6/E6AP/p53 complex that is required for HPV-
mediated degradation of p53 was solved recently using 
a mutated full-length E6 protein (named as HPV16 E6 
4C/4S), the LxxLL motif of E6AP, and the core domain 
of p53 [29].
In the present study, we developed a procedure for 
production of the HPV16 His6-E6 protein in its wild-
type but soluble form and at high yields. The structural 
properties of this novel His6-E6 protein were examined 
using UV, circular dichroism (CD), and fluorescence 
spectroscopy, with its aggregation in solution examined 
using 90° light scattering. Binding investigations with 
p53, PDZ1 (from MAGI-1), hDLG and E6AP using GST 
pull-down assays showed that this native His6-E6 protein 
retains its biological activity, which was also confirmed 
using in  vitro degradation assays. Large amounts of the 
His6-E6 protein were obtained by modulation of several 
chemicophysical parameters and solvent conditions (e.g., 
temperature, oxidation–reduction conditions, buffer pH, 
detergents), which were also applied to the His6-E6 pro-
tein from HPV18 and HPV11. Furthermore, this novel 
His6-E6 protein was able to induce a stronger humoral 
immune response in immunized C57BL/6 mice than the 
His6-E6 protein prepared in its denatured form.
This study thus provides a method to produce a solu-
ble, stable and functional E6 oncoprotein that might 
represent a novel tool for HPV diagnosis and therapy. 
Moreover, it opens up the possibility to obtain further 
information about the structure and functions of E6.
Methods
Bacterial strains and recombinant DNA techniques
The E. coli strains XL1 Blue, M15[pREP4], BL21(DE3), 
and JM109 were grown in Luria–Bertani broth (LB; 
Sigma-Aldrich Italia, Milan, Italy) or on LB agar plates, 
in the presence of 50 mg/L kanamycin or 100 mg/L ampi-
cillin. Escherichia coli competent cells were transformed 
using standard methods. The plasmid DNA isolated 
from selected clones was purified using plasmid purifica-
tion kits (Qiagen, Hilden, Germany) and analyzed using 
restriction enzymes (New England Biolabs Ltd, Ontario, 
Canada) and DNA sequencing.
Construction of expression plasmids
The E6 genes from HR-HPV16, HR-HPV18, and LR-
HPV11 were cloned in the pQE30 E. coli expression vec-
tor (Qiagen) to allow expression of the 6×  His-tagged 
recombinant proteins. The encoding DNA fragments 
were obtained from the pGEX plasmid using BamH I 
and Not I, and were ligated to pQE30 that had previously 
been cut with the same restriction endonucleases.
Construction of co‑expression plasmids
The chaperone plasmid set from Clontech (Takara Bio 
Company, Mountain View, USA) was used. The kit con-
sists of five different plasmids, with each one designed to 
express multiple molecular chaperones to enable optimal 
protein expression and folding. In particular, chaperone 
A was designed to express the products of the dnaK-
dnaJ-grpE groES-groEL genes, chaperone B for the groES-
groEL genes, chaperone C for the dnaK-dnaJ-grpE genes, 
chaperone D for the groES-groEL-tig genes, and chaper-
one E for the tig gene (Table 1). The preparation of a sys-
tem to co-express the target HPV16 His6-E6 protein and 
one of the chaperones was carried out according to the 
manufacturer specifications.
The different E. coli strains were transformed with the 
pQE30-HPV16 His6-E6 expression plasmid along with 
one of each of these different chaperones. Each trans-
formant that contained both plasmids (one expressing 
the HPV16 His6-E6 gene, and one expressing one of the 
chaperones) was induced. Purification was performed 
by affinity chromatography using Ni-nitrilotriacetic 
acid agarose resin (Ni-NTA; Qiagen). The total amount 
of His6-E6 was determined by sodium dodecyl sulfate-
poly acrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting.
Set‑up of optimal parameters for expression 
and purification of the native His6‑E6 protein
The His6-E6 protein was initially expressed for 3 h at 37 °C 
in the E. coli XL1 Blue strain in the absence of any chap-
erone. The induction and purification were performed by 
changing different chemico-physical parameters (Table 2, 
Protocols A–E), and by analyzing the products obtained 
using SDS-PAGE and immunoblotting. In particular, to 
improve the oxidation–reduction conditions and to avoid 
oxidation of free cysteines, 100 µM dithiothreitol (DTT) 
was added to the purification buffers. Buffers with lower 
pH than in standard protocols and with higher imidazole 
concentrations were also used, to move away from the 
HR-HPV16 E6 isoelectric point (pI = 9.24) and to better 
protect against contaminants [30].
After optimization of the protocol, the His6-E6 protein 
was expressed overnight at 28  °C in E. coli JM109 with 
pTf16 (chaperone E, which expressed the trigger factor 
molecule; TF), which allowed high protein yields and 
facilitated its handling. The overnight culture was 100-
fold diluted in fresh LB with 20  mg/L chloramphenicol 
and 100 mg/L ampicillin, and incubated at 37 °C until an 
OD600 of 0.6–0.7 was reached. Protein expression was 
induced with 1 mM isopropyl-β-d-thiogalactopyranoside 
(IPTG; Qiagen), and the cells were grown at 28  °C for 
16  h before harvesting by centrifugation at 4000×g for 
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20  min at 4  °C. The pellet harvested from a 5-L bacte-
rial culture was resuspended in lysis buffer (50  mM 
NaH2PO4, 200  mM NaCl, 20  mM imidazole, 100  µM 
DTT, pH 7.5) containing EDTA-free protease inhibi-
tors (complete protease inhibitor cocktail tablets; Roche, 
Basel, Switzerland) at the concentration recommended 
by the manufacturer. After adding 1  mg/mL lysozyme 
and 1 % Triton X-100, the cells were incubated for 1 h at 
4 °C, and then sonicated on ice at a 10-Hz output (3× for 
1 min) in an ultrasonic disintegrator (Soniprep 150, MSE, 
UK). Clarification was performed by centrifugation at 
15,000×g for 45  min at 4  °C, and the supernatant was 
incubated for 16  h with 1  mL Ni-NTA that had previ-
ously been equilibrated in lysis buffer. After washing the 
Ni-NTA several times with 50  mM NaH2PO4, 200  mM 
NaCl, 70 mM imidazole, 100 µM DTT, pH 7.5, to reach 
a final OD280 of 0.01, the protein was eluted from the Ni-
NTA using 50  mM NaH2PO4, 200  mM NaCl, 300  mM 
imidazole, 100 µM DTT, pH 7.5. The different fractions 
were run on 15 % SDS-PAGE.
To improve the solubility of the purified His6-E6 onco-
protein, different detergents were added to the elution 
fractions and to the dialysis buffer at low concentrations, 
including 0.02 % lauryl-β-D-maltoside, 0.02 % Tween-20, 
0.02 % glycine, 0.02 % betaine, and 0.1 M arginine, with 
the aim being to mask the hydrophobic surface groups of 
the purified His6-E6 protein. After addition of each deter-
gent to different aliquots of the same preparation of the 
purified His6-E6 protein, the preparations were analyzed 
before and after dialysis, as well as after high-speed cen-
trifugation. The fractions enriched in the recombinant 
His6-E6 protein were pooled, dialyzed against Ca2+-
free and Mg2+-free phosphate-buffered saline (PBS–) 
containing 0.02  % betaine, 100  µM DTT, pH 7.5, and 
concentrated using 10-kDa cut-off centriprep centrifuga-
tion (Amicon, Merck Millipore, Darmstadt, Germany). 
The concentration of the purified His6-E6 protein was 
determined by absorbance at 280  nm, using the molar 
extinction coefficient of His6-E6 (i.e., 21,275 M−1 cm−1), 
calculated according to Gill and von Hippel [31]. Puri-
fied proteins were quantified in Coomassie-stained SDS-
PAGE by comparison with 0.25, 0.5 and 1 μg of BSA run 
in the same gel. The purified His6-E6 protein was stored 
at 4 °C until use.
To evaluate the purity of the protein samples, they were 
denatured by boiling for 3 min in 2× SDS sample buffer 
Table 1 Different combinations of molecular chaperones and E. coli strains tested for HPV His6-E6 expression
± Qualitative estimation of yield
a All combinations included the pQE30 HPV16 His6-E6 plasmid
b Chaperone A carried the dnaK-dnaJ-grpE groES-groEL genes, B the groES-groEL genes, C the dnaK-dnaJ-grpE genes, D the groES-groEL-tig genes, E the tig gene
E. coli strain Combinationa according to chaperoneb (plasmid)
A (pG‑KJE8) B (pGro7) C (pKJE7) D (pG‑Tf2) E (pTf16)
M15 [pREP4] – ++ ++++ – ++
BL21 (DE3) – ++ + – +
JM109 + +++ + – +++++
Table 2 Chemical and physical parameters analyzed during the purification of the HPV16 His6-E6 protein under native 
conditions
a The detergents listed were tested individually
Protocol Temperature (°C) Dithiothreitol (µM) pH Imidazole (mM) Detergenta
Lysis buffer Wash buffer Elution buffer
A Room temperature – 8 10 20 250 –
B 4 100 8 10 25 250 –
C 4 100 8 20 50 250 –
D 4 100 7.5 20 70 300 –
E 4 100 7.5 20 70 300 0.02 % lauryl-β-D-maltoside
0.02 % Tween-20
0.02 % glycine
0.02 % betaine
0.1 M arginine
F 4 100 7.5 20 70 300 0.02 % betaine
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(100 mM Tris–HCl, pH 6.8, 200 mM DTT, 4 % SDS, 20 % 
glycerol, 0.02 % bromophenol blue), separated using 15 % 
SDS-PAGE, and stained using Coomassie blue.
Immunoblotting
The purified proteins in 2× SDS sample buffer were sepa-
rated by SDS-PAGE and transferred onto PVDF mem-
branes (Millipore, Darmstadt, Germany). The primary 
antibody was anti-E6 mouse polyclonal serum produced 
according to a previously published protocol [32] and 
utilized at a 1:1000 dilution [33]. The secondary antibody 
was a horseradish peroxidase (HRP)-conjugated sheep 
anti-mouse IgG antibody (1:10,000 dilution; GE Health-
care, Buckinghamshire, UK). Proteins were visualized 
using the chemiluminescent HRP substrate (Millipore, 
Darmstadt, Germany).
UV, circular dichroism and fluorescence emission 
spectroscopy
The UV–visible spectra were recorded using a double-
beam spectrometer (Lambda 16; Perkin-Elmer Life Sci-
ences) that was equipped with a thermal controller 
(Peltier) set at 20 °C.
The CD spectra were recorded at 20  °C using a spec-
tropolarimeter (Jasco J-720) equipped with a thermal 
controller (Peltier). Far-UV-CD spectra (190–250  nm) 
were measured in a 0.1–0.02-cm-path-length quartz 
cuvette, and near-UV-CD spectra (250–310  nm) in 
a 1.0-cm-path-length quartz cuvette. The data are 
expressed as the mean residue ellipticity ([Θ]), assum-
ing a molecular weight of 110  Da for each amino-acid 
residue.
The measurements of the intrinsic fluorescence emis-
sion and 90° light scattering were carried out at 20  °C 
in a spectrofluorimeter (LS50B; PerkinElmer Life Sci-
ences, Waltham, USA) using a 1-cm-path-length quartz 
cuvette. The intrinsic fluorescence emission spectra were 
recorded from 300 to 450  nm (at 1-nm sampling inter-
vals) with the excitation wavelength at 290 nm. In all of 
the experiments, the slit widths were set to 3 nm for exci-
tation and 5 nm for emission. The 90° light scattering was 
recorded at the wavelength of 480 nm both for excitation 
and emission.
The spectra were accumulated four times. All of the 
values were corrected for solvent contributions (PBS– 
containing 100 µM DTT, 0.02 % betaine). The analysis of 
the far-UV-CD spectra was performed using the Dicro-
prot program [34] and the Dicroprot server [35], and by 
comparing different methods.
GST pull‑down assay
In vitro GST pull-down assays were used to determine 
any interactions between the E6 protein and its cellular 
protein targets (i.e., p53, PDZ1 from MAGI-1, hDLG, 
E6AP), expressed in E. coli XL1 as GST-fusion proteins. 
Briefly, E. coli XL1 were grown overnight (16 h), 100-fold 
diluted in fresh LB with 100 mg/L ampicillin, and incu-
bated at 37  °C until an OD600 of 0.6–0.8 was reached. 
The expression of the recombinant proteins was induced 
with 1  mM IPTG for 3  h at 37  °C. The proteins were 
then purified and immobilized on glutathione-agarose 
(Sigma-Aldrich). All of the immobilized GST-fusion pro-
teins were run on SDS PAGE to evaluate the amount of 
each protein. Similar amounts (as evaluated by Coomas-
sie stained gels) of the GST- fusion proteins GST-p53, 
GST-PDZ1, GST-hDLG, GST-E6AP and GST-alone (as 
negative control) were incubated with 50  ng of E6 pro-
teins from HPV16, HPV18, and HPV11 for 2 h at 4 °C, to 
determine any binding interactions.
After removing the supernatant, the resin was washed 
five times with PBS– containing 0.25 % Nonidet-P 40. The 
assays were carried out three times. The purified His6-E6 
protein (20  ng) from HPV16, HPV18, and HPV11 was 
used as a positive control. The proteins were analyzed 
using SDS-PAGE and immunoblotting.
In vitro transcription‑translation and degradation assays
The DNA of pSP64-HPV16 E6, pSP64-p53-pro and 
pCDNA3-MAGI-3 plasmids was transcribed and trans-
lated in  vitro in a rabbit reticulocyte lysate (Promega 
TNT System, Madison, Wisconsin, USA), following 
the manufacturer instructions, with radiolabeling with 
0.6 mCi/mL 35[S]-cysteine (GE Healthcare). The transla-
tion efficiency was monitored by analyzing 1 µL aliquots 
of each protein using SDS-PAGE and PhosphorImager 
analysis (Fujifilm, Milano, Italy).
In the standard in  vitro degradation assay [36], deg-
radation was monitored by mixing the translated target 
proteins with 50  ng of the purified His6-E6 protein at a 
3:1 ratio with an incubation at 25 °C. After 1 h and 2 h, 
5-µL aliquots were removed from the reaction mix-
tures and analyzed. All volumes were equalized using 
the water-primed reticulocyte lysate TNT mix (Pro-
mega). The samples were added to 5×  loading buffer 
(250 mM Tris–HCl, pH 6.8, 10 % SDS, 30 % glycerol, 5 % 
β-mercaptoethanol, 0.02  % bromophenol blue), boiled 
and analyzed using SDS-PAGE and autoradiography. The 
degradation experiments were carried out three times, 
and the relative quantification was performed with a 
PhosphorImager by measuring the signal intensities of 
protein bands.
Animal immunization with the HPV16 His6‑E6 protein
Female 6–8-week-old C57BL/6 mice were used (Charles 
River; Como, Italy). Groups of five mice were injected 
subcutaneously on days 0, 7, 15, and 21. Each mouse was 
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inoculated with a 100 µL volume containing 20 µg puri-
fied HPV16 His6-E6 protein, as produced under native or 
denaturing conditions, plus Freund incomplete or MF59 
adjuvant. Saline solution was used for the control group. 
The mice were maintained under specific pathogen-free 
conditions, following the institutional guidelines.
ELISA
Serum samples were collected from the immunized mice 
1 week after the fourth boost. Sera from the mice in the 
same group were pooled and analyzed for E6-specific 
antibodies using ELISA, as described previously [37]. 
Briefly, 96-well maxisorp microtiter plates (Nunc, Naper-
ville, IL, USA) were coated with the His6-E6 protein 
(200 ng/well, in PBS– or carbonate buffered saline). The 
sera were diluted 1:100 in 2 % milk PBS, and the binding 
was detected using a HRP-conjugated sheep anti-mouse 
IgG antibody (1:10,000; GE Healthcare, Buckingham-
shire, UK). The immunocomplexes were revealed by 
addition of the 2,2 azino-di-3-ethylbenz-thiazoline sul-
fonate substrate (Sigma-Aldrich), and the absorbance 
was read at 450 nm using a microtiter plate reader (Bio-
Rad Laboratories, Hercules, CA, USA).
Statistical analyses
Statistical analyses were performed using one-way 
ANOVA parametric tests and Bonferroni analysis of vari-
ance, using the GraphPad Prism 5 software. The signifi-
cance was set as p < 0.05 (*), p < 0.01 (**), and p < 0.001 
(***).
Results
Glycine, arginine and betaine detergents reduce 
degradation of the HPV16 E6 protein produced 
under native conditions
With the aim to develop a standard protocol for expres-
sion and purification of the His6-E6 protein from dif-
ferent HPVs, the HPV16 His6-E6 protein was initially 
purified from inclusion bodies under denaturing condi-
tions using immobilized metal-affinity chromatography. 
After dialysis, this His6-E6 protein showed a strong ten-
dency to form insoluble aggregates, which generated a 
visible precipitate (data not shown). However, after low-
ering the temperature and adding DTT as a reducing 
agent, the His6-E6 protein was maintained in solution 
for a few hours. Other chemical and physical parameters 
were then varied (Table 2, Protocols A–E) to improve the 
characteristics of this His6-E6 protein. In the presence of 
lauryl-β-D-maltoside or Tween-20, the His6-E6 protein 
tended to be degraded, particularly soon after the dialysis 
and high-speed centrifugation, while the addition of gly-
cine significantly reduced this degradation after dialysis 
and centrifugation (Fig. 1a, b). In particular, Fig. 1c shows 
that when arginine or betaine were included before 
dialysis (Fig. 1c, lanes 1), after dialysis (Fig. 1c, lanes 2), 
and after the high-speed centrifugation (Fig.  1c, lanes 
3), only a single band of the expected molecular weight 
was detected by a HPV16 E6-specific serum [32, 33], 
thus demonstrating the absence of protein degradation. 
Figure  1d shows the SDS-PAGE of the HPV16 His6-E6 
protein purified through this optimized protocol, and 
Table  2 indicates the different systems that were tested 
before the novel final purification procedure (Protocol F).
HPV16 His6‑E6 protein expression and purification are 
enhanced in the E. coli JM109 strain and with TF chaperone 
co‑expression
To further enhance the His6-E6 expression levels, dif-
ferent E. coli strains were transformed with the HPV16 
His6-E6 gene and different chaperone plasmids, for chap-
erone co-expressed. The results show that after induction 
with chaperones A to C, His6-E6 expression was always 
low with the E. coli BL21 strain, and improved with chap-
erone C and the E. coli M15 strain. However, the best 
results were obtained again using the TF chaperone with 
the E. coli JM109 strain (Table 1, chaperone E). This most 
favorable combination improved the His6-E6 protein 
yield, which resulted in the production of about 1.5 mg 
of HPV16 His6-E6 protein from 24  g of pelleted E. coli 
JM109 from 5 L of culture.
The induction of His6-E6 in E. coli JM109 was then ana-
lyzed by immunoblotting.
After induction with chaperones A to C (Fig.  2a–c), 
His6-E6 expression was comparable to that obtained 
in the absence of chaperones (Fig.  2a, w/o) whereas it 
was very low, or even absent, when using chaperone 
D (Fig.  2a, d). Conversely, the use of the TF chaperone 
greatly enhanced the His6-E6 production (Fig.  2a, e). 
When the His6-E6 protein produced in E. coli JM109 
with this TF chaperone were purified (Fig. 2b), there was 
more His6-E6 in the presence (Fig. 2b, with chaperones) 
than in the absence (Fig. 2b, w/o) of the chaperone. The 
conditions shown in Fig. 2b included 1 and 3 µL of these 
protein samples (lanes 1 and 2, respectively), with the 
His6-E6 protein purified under denaturing conditions 
used as the positive control (Fig.  2b, c+). Faint bands, 
corresponding to the molecular weights of E6 dimer and 
trimer, are also detectable.
Spectroscopic analysis reveals the structure of the HPV16 
His6‑E6 protein purified under native conditions
The HPV16 His6-E6 structure in solution was evalu-
ated using CD and fluorescence emission spectroscopy 
(Fig.  3). The far-UV-CD spectrum was characterized 
by low ellipticity, a zero intercept at 203  nm, and simi-
lar contributions at 222 and 208  nm (Fig.  3a). These 
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far-UV-CD spectral features are typical of proteins that 
have few elements of periodic secondary structure. The 
analysis of the far-UV-CD spectra identified approxi-
mately 12  % α-helices, 35  % β-sheets and 53  % random 
coils. The near-UV-CD spectrum of His6-E6 (Fig.  3b) 
showed broad ellipticity bands that were poorly resolved, 
at around 266 nm due to the presence of phenylalanine 
residues, and at around 292  nm, as a region that can 
generally be ascribed to tryptophan residues. In addi-
tion, a very large but poorly defined band of positive 
ellipticity was observed above 300  nm. The intrinsic 
fluorescence spectra of His6-E6 was recorded at 290 nm 
excitation wavelength, and this revealed maximum emis-
sion at 338  nm, a wavelength that is lower than that of 
tryptophan in water (around 350 nm) (Fig. 3c). No par-
ticle aggregation was detectable by 90° light scattering at 
480 nm (data not shown).
HPV His6‑E6 proteins purified under native conditions are 
stable
Once the protocol was set up for HPV16 His6-E6, the 
same protocol was used for the purification of the 
His6-E6 protein from HR-HPV18 and LR-HPV11. Only 
one chromatographic step was necessary to purify the 
His6-E6 proteins from HPV16, HPV18, and HPV11 
to homogeneity (i.e.,  ~90  %), as shown by Coomas-
sie blue staining following SDS-PAGE (Fig.  4a, lanes 2, 
3, 4, respectively). Denatured HPV16 His6-E6 was used 
as the control (Fig.  4a, lane 1). No protein degradation 
was observed in the immunoblots of the His6-E6 pro-
teins purified under native conditions from HPV18 and 
HPV11 both before (Fig. 4b, lanes a) and after (Fig. 4b, 
lanes b) the dialysis and concentration steps. The con-
centrated HPV16 His6-E6 protein was used as the con-
trol here (Fig. 4b, c+).
Fig. 1 Effects of detergents on HPV16 His6-E6 solubility. Representative immunoblots of the soluble HPV16 His6-E6 protein before dialysis (lanes 1), 
after dialysis (lanes 2), and after high-speed centrifugation (lanes 3), in the absence of detergent (a) and with addition of lauryl-β-D-maltoside (a), 
glycine (b), Tween-20 (b), arginine (c) and betaine (c). C+ , HPV16 His6-E6 protein purified under denaturing conditions. (d) Representative SDS-
PAGE of the HPV16 His6-E6 protein purified through the optimized protocol
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HPV His6‑E6 proteins purified under native conditions 
show biological activity
To determine whether the HPV His6-E6 proteins from 
HR-HPV16, HR-HPV18 and LR-HPV11 retain biologi-
cal activity through this new purification protocol, these 
proteins were purified under native conditions and ana-
lyzed in vitro using GST pull-down assays for the GST-
hDLG, GST-E6AP, GST-p53, and GST-PDZ of MAGI-1 
fusion proteins purified from E. coli on glutathione 
agarose (Fig.  5, lanes 2, 3, 4, 5, respectively). The bind-
ing activities toward these cellular proteins showed that 
HPV16 His6-E6 bound its most important cellular tar-
gets mainly as a monomer (Fig.  5a), whereas HPV18 
His6-E6 bound hDLG, p53, and PDZ1 both as a mono-
mer and a dimer (Fig. 5b, lanes 2, 4, 5), but did not bind 
E6AP (Fig. 5b, lane 3). Conversely, there were no interac-
tions between LR-HPV11 His6-E6 and the tested targets 
(Fig. 5c). The purified His6-E6 proteins that were used as 
the positive controls showed dimeric bands for all of the 
HPVs (Fig. 5, lanes 6), whereas there were no bands with 
free GST protein, used as the negative control (Fig.  5, 
lanes 1).
HPV His6‑E6 proteins purified under native conditions can 
degrade their targets
The in vitro translational efficiencies of MAGI-3, HPV16 
E6, and p53 before their use in the degradation assays 
are shown in Fig. 6a, lanes 1, 2, 3, respectively. The HPV 
His6-E6 purified proteins were then mixed with either 
MAGI-3 (Fig. 6b) or p53 (Fig. 6c), to determine whether 
they degraded these target proteins. Aliquots of each 
reaction mixture after incubations of 1  h (T1) and 2  h 
(T2) were analyzed by SDS-PAGE. When MAGI-3 was 
combined with HPV16 or HPV18 His6-E6, a very weak 
band for MAGI-3 was seen at T1 that had almost disap-
peared at T2. In contrast, this band was seen at both T1 
and T2 for HPV11 His6-E6 (Fig. 6b). Similar results were 
observed with p53, where a very weak p53 band was seen 
at T1 for all three HPV His6-E6 proteins, but only for 
HPV11 His6-E6 at T2. As controls, MAGI-3 and p53 pro-
teins were incubated in the absence of His6-E6 and the 
in vitro translated HPV16 E6 protein alone was used in 
the incubations (Fig.  6). Reported data are the result of 
three independent experiments (Fig. 6d).
His6‑E6 protein in its native form induces a better humoral 
immune response than in the denatured state
The immunogenicity of the HPV16 His6-E6 protein was 
tested in vivo in a mouse model. As shown in Fig. 7, the 
mice were immunized with denatured or native purified 
His6-E6 with either Freund incomplete or MF59 adju-
vant, with the control mice injected with PBS– with the 
adjuvants. All of the mice received four subcutaneous 
inoculations, and a week after the last inoculation they 
were sacrificed and analyzed for the presence of anti-
bodies against His6-E6. The mice immunized with native 
His6-E6 showed significantly higher titers of specific 
antibodies compared to those immunized with His6-E6 
Fig. 2 Effects of different chaperones on HPV His6-E6 expression 
levels. Representative immunoblots of induction and purification of 
HPV16 His6-E6 produced in E. coli JM109. a Bacterial transformation 
with the pQE30-HPV16 His6-E6 expression plasmid alone (w/o) or 
with the different chaperone systems (chaperones A–E, see Table 2). 
Total proteins were extracted by re-suspension in SDS-loading buffer 
of E. coli cell cultures, according to their OD600. b Purification of the 
HPV16 His6-E6 protein without chaperones (w/o) and with the trigger 
factor chaperone (with chaperones; chaperone E, see Table 2). M 
ColorBurst, Sigma, lanes 1 1 µL, lanes 2 3 µL, lane 3 C+, 20 ng of puri-
fied His6-E6 protein positive control
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produced under denaturing conditions (Fig. 7; p < 0.001) 
and to the control mice (Fig. 7; p < 0.001). There were no 
significant differences seen between the use of the Fre-
und incomplete or MF59 adjuvants.
Discussion
HR-HPVs are responsible for more than 550,000 new 
cases of cervical cancer each year, and have also been 
implicated in vaginal, vulvar, and penile cancers. A strong 
link also exists between infection by HR-HPVs and the 
development of anal and oropharyngeal tumors [4].
Although the HPV E6 protein has been studied for 
several decades, the crystallographic structure was only 
recently solved for the HPV16 E6 protein with a modi-
fied amino-acid sequence and stabilized by fusion with 
the cellular LxxLL motive of E6AP [28]. A key to success-
ful analysis of the structure and function of a recombi-
nant protein is its efficient expression and purification, 
which is also an important goal for the development of 
therapeutic drugs. For this purpose, E. coli is the most 
commonly used host for the expression of recombinant 
proteins, although these proteins are often produced in 
inclusion bodies where they can assume an insoluble, 
non-native conformation.
Production of the full-length E6 protein as inclusion 
bodies is relatively easy, and our preliminary expression 
and purification also showed that this E6 protein was 
present in visible aggregates, with the soluble and native 
conformations of E6 difficult to obtain. To overcome 
this problem, the temperature was the first parameter 
considered here, as it represents a fundamental condi-
tion through purification steps, and as different proteins 
have various degrees of thermal stability. This was kept 
at 4  °C, to guarantee the solubility of the E6 protein. To 
prevent His6-E6 denaturation or degradation, the pH was 
also varied in the different protocols. This was defined 
on the basis of keeping it closer to the intracellular pH 
and far from the E6 isoelectric point, as proteins show 
minimum solubility at their isoelectric point. In this way, 
after affinity chromatography with Ni-NTA, the His6-
E6 oncoprotein was recovered in a highly purified form 
(~90  %), which was aided by the addition of increasing 
concentrations of imidazole to the purification buffers. 
Also, 100 µM DTT was added to the purification buffer 
as a reducing agent, to prevent the formation of disulfide 
bridges between the several cysteine residues of the E6 
amino-acid sequence. Low levels of different detergents 
were also tested, to improve the His6-E6 solubility after 
purification, where glycine, arginine and betaine also 
prevented protein degradation. This appeared to occur 
through hindering the formation of the hydrophobic 
interactions that lead to His6-E6 aggregation and pre-
cipitation. Betaine was finally adopted as the detergent of 
choice to improve the protein solubility, as it also did not 
interfere with the spectroscopic analyses [38].
By combining these parameters in this novel purifica-
tion protocol, visible aggregation was no longer present, 
and the His6-E6 protein remained soluble and stable for 
more than 2 years at 4 °C (Fig. 4c).
This protocol was also applied to the purification 
of the HPV18 and HPV11 His6-E6 proteins, although 
lower yields were obtained for the LR-HPV E6 protein, 
which might be explained by its lower isoelectric point 
(pI = 8.44) compared to HR-HPV E6 (pI = 9.24).
To enhance the His6-E6 protein expression levels, dif-
ferent E. coli strains were also tested and combined with 
different molecular chaperones. It is known that chap-
erones can assist in the covalent folding/unfolding and 
assembly/disassembly of other macromolecular struc-
tures, and several chaperone systems can carry out a 
multitude of functions, all of which are aimed at insur-
ing correct folding of the target proteins [39]. The highest 
Fig. 3 Spectral properties of the HPV16 His6-E6 protein. a Far-UV-CD spectrum. b Near-UV-CD spectrum. c Intrinsic fluorescence emission spectrum 
(290 nm excitation). All spectra were recorded at 20 °C in PBS− containing 100 µM DTT and 0.02 % betaine
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HPV16 His6-E6 protein yield was obtained using the E. 
coli JM109 strain plus the TF chaperone molecule, which 
is crucial in the first step of protein synthesis and assists 
protein folding mainly by accelerating peptidyl-prolyl 
cis-trans isomerization [40]. Due to the relatively high 
proline content of the E6 protein (HPV16, HPV18, and 
HPV11 contain 7, 6, and 4 proline residues, respectively), 
the isomerization of peptide bonds with proline might be 
fundamental for its folding.
The HPV16 His6-E6 protein conformation was then 
analyzed by spectroscopy. This analysis revealed a low 
content of periodic secondary structure, which might be 
in agreement with the binding of E6 to many target pro-
teins. The positive ellipticity band at >300 nm might be 
due to the effects of disulfides as chromophores, as pre-
viously described by Mulkerrin [41] and Hennecke [42]. 
The low degree of periodical secondary structure of the 
HPV16 His6-E6 protein was accompanied by its poorly 
defined tertiary arrangement, as determined by near-UV-
CD, while the fluorescence spectrum suggested that the 
tryptophan residue was not exposed to the solvent. This 
might be explained according to bioinformatic studies on 
the HPV proteome (E6 and E7 oncoproteins in particu-
lar) where it emerged that these proteins can be traced 
back to a family of intrinsically disordered proteins [43]. 
Taken together, these analyses suggest that HPV16 His6-
E6 retains correct folding and conformational properties.
HPV16 His6-E6 also appeared to be functional in 
terms of its activity. Different assay systems were used 
to confirm the functionality of the HPV His6-E6 pro-
teins, including their interactions with E6AP, p53, and 
PDZ domains (i.e., DLG, MAGI-1), and their degrada-
tion of p53 and MAGI-3. When the His6-E6 oncoproteins 
were used in the GST pull-down assays, a second, higher 
molecular weight band was seen (in particular for HPV18 
His6-E6), which corresponded to their dimeric forms. 
Considering the oxidation-prone behavior of the E6 
Fig. 4 Purification of the HPV His6-E6 proteins under native condi-
tions. The optimized protocol for HPV16 His6-E6 protein production 
was applied to the E6 protein from the different HPVs. a Coomassie 
blue staining of representative SDS-PAGE of purified E6 protein from 
HPV11 (lane 2), HPV16 (lane 3) and HPV18 (lane 4) after one chroma-
tographic step. Lane 1, HPV16 His6-E6 protein produced under dena-
turing conditions, as control. b Representative immunoblot of the 
HPV18 and HPV11 His6-E6 proteins purified under native conditions 
before (a) and after (b) dialysis and concentration. C+ , concentrated 
HPV16 His6-E6 protein, as control. c Coomassie blue staining of rep-
resentative SDS-PAGE of HPV16 His6-E6 protein stored for more than 
2 years at 4 °C (lane 1) and −20 °C (lane 2)
Fig. 5 Physical interactions between purified HPV His6-E6 proteins and their cellular targets. Representative immunoblots from GST pull-down 
assays of the His6-E6 proteins from HR-HPV16 (a), HR-HPV18 (b), and LR-HPV11 (c) for the GST-fusion proteins for DLG (lanes 2), E6AP (lanes 3), p53 
(lanes 4), and PDZ of MAGI-1 (lanes 5). Lanes 1 GST-protein as negative controls, lanes 6 purified His6-E6 proteins, as positive controls
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Fig. 6 In vitro degradation of p53 and MAGI-3 by HPV His6-E6 proteins. HPV16 E6, MAGI-3, and p53 proteins were in vitro translated in rabbit 
reticulocyte lysates. a Representative autoradiography for these 35[S]-cysteine-radiolabeled proteins following SDS-PAGE for the protein translation 
efficiencies (as indicated). b, c Representative SDS-PAGE for degradation of MAGI-3 (b) and p53 (c) following their mixing with purified HPV His6-E6 
proteins (as indicated). The reaction mixtures were sampled after 1 h (T1) and 2 h (T2) of incubation. INPUT without purified His6-E6 protein, E6 IVT 
in vitro transcribed E6 protein from HPV16, as positive control (d). Quantification of MAGI-3 and p53 degradation was achieved by measuring the 
signal intensities of protein bands with a PhosphorImager. Data represent the mean of three independent experiments ± standard deviations. 
Values are presented relative to the amount of MAGI-3 or p53 in the presence of water-primed reticulocyte lysate, after 2-h incubation
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protein, such dimers probably form via cysteine bonds, 
which suggests that higher concentrations of reduc-
ing agents in the storage buffer might help to keep these 
His6-E6 proteins in the monomeric form. It has also been 
reported that the HPV11 E6 protein can bind p53 and 
E6AP [44], but in the present study, no such interactions 
were observed between HPV11 His6-E6 and the targets 
included here.
To determine the immunogenicity of the native His6-
E6 protein, mice were immunized using HPV16 His6-E6 
combined with two alternative adjuvants, Freund incom-
plete or MF59. Only the His6-E6 produced under native 
conditions induced strong humoral responses, with no 
significant difference between the use of these two adju-
vants. Thus, these data might indicate that the E6 with a 
non-conformational structure lost its immune-dominant 
antigenic sites, and suggest that the native E6 protein 
might be more useful as an immunogen.
In summary, the results from the present study thus 
indicate that: (i) the E6 protein produced in its native con-
dition is protected from degradation by glycine, arginine, 
and betaine; (ii) His6-E6 protein expression levels and 
purification are enhanced in the E. coli JM109 strain and 
with TF chaperone co-expression; (iii) the spectroscopic 
analysis confirms the native structure of the purified 
HPV16 His6-E6 protein; (iv) the purified His6-E6 protein 
shows biological activity; (v) His6-E6 binds to the cellular 
target proteins that are responsible for E6 oncogenic activ-
ity, and it can promote in vitro degradation of the MAGI-3 
and p53 cellular targets; and (vi) only the native His6-E6 
protein induces good humoral immune responses.
Conclusions
This novel protocol designed around a prokaryotic 
expression system allows biologically active His6-E6 pro-
teins from HR-HPV16, HR-HPV18, and LR-HPV11 to be 
obtained at high yields in their native, soluble and stable 
forms. In particular, the purified HPV16 His6-E6 protein 
was stable for more than 2  years when stored at 4  °C, 
and was immunogenic in the mouse model. This antigen 
might also be useful to obtain monoclonal or polyclonal 
antibodies, which are still lacking as reagents for in vivo 
(e.g., ‘imaging’) or in vitro (e.g., immunoblotting, immu-
nohistochemistry) diagnosis. This new procedure (that 
was set up through the present study) might also be use-
ful to prepare the E6 protein for immunotherapy of HPV-
related cancers, and to favor its industrial production for 
diagnostic tests (i.e., Luminex technologies).
With this aim, the maintenance of the native confor-
mation of the E6 protein should improve the specificity, 
costs, precision, and reproducibility in the detection of 
anti-E6 antibodies in patient sera.
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